Skip to content
Browse

Edition

Sections

Appearance

AboutSourcesContactPrivacy

Amplia gets nod for new cancer drug trial ahead of US push

Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

First reported by The Age Latest report 2 sources
Image: The Age
Image: The Age
Read at The Sydney Morning Herald(opens in a new tab)

Full coverage

Every report we found on this story, oldest first. Each links to the original publisher.

  1. The Age

    Amplia gets nod for new cancer drug trial ahead of US push (opens The Age in a new tab)

    Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

  2. The Sydney Morning Herald

    Amplia gets nod for new cancer drug trial ahead of US push (opens The Sydney Morning Herald in a new tab)

    Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.

Something wrong with how we've grouped or summarised this story? Report a problem